MarketCapExport financials
Protara Therapeutics (TARA)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Protara Therapeutics Balance Sheet 2025-2009 | TARA
Brief overview of Protara Therapeutics's balance sheet structure
This overview follows the five latest available annual observations between 2021 and 2025.
Assets added +21.4%, reaching $209.5 million from $172.6 million five periods earlier; annual growth near 5% remained solid.
Liabilities followed the scale of the balance sheet: +22.2% versus +21.4% for assets. Leverage did not change materially.
Equity accounts for 93.8% of assets. Against the initial 93.8%, the capital position looks resilient.
Negative net debt of -$46.3 million means cash holdings are larger than debt obligations.
Cash represents 23.7% of assets versus 20.7% initially, showing how the immediate liquidity reserve changed.
Retained earnings are negative at -$302.4 million. This reduces the formal capital cushion, although large shareholder returns may have contributed.
Conclusion
Protara Therapeutics's financial position is more positive than negative: the funding mix is workable, although the cushion is not unlimited.
Annual Balance Sheet Protara Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-46.3 M | -158 M | -34.1 M | -17.7 M | -28.5 M | -168 M | -6.18 M | -19.4 M | -21.2 M | -36.4 M | -40 M | -68.8 M | - | - | - | - |
Long Term Debt |
2.12 M | 3.36 M | 4.48 M | 5.47 M | 6.38 M | - | - | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
1.24 M | 1.12 M | 983 K | 917 K | 855 K | 88 K | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | 999 K | - | - | - | - | - | - | - | - | - | - |
Total Current Liabilities |
10.9 M | 11 M | 6.15 M | 5.74 M | 4.3 M | 2.92 M | 583 K | 3.08 M | 9.24 M | 5.08 M | 4.13 M | 2.34 M | - | - | - | - |
Total Liabilities |
13.1 M | 14.3 M | 10.6 M | 11.2 M | 10.7 M | 3.91 M | 583 K | 3.08 M | 9.24 M | 5.08 M | 4.13 M | 2.34 M | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.9 M |
Retained Earnings |
-302 M | -245 M | -200 M | -160 M | -94 M | -46.8 M | -225 M | -210 M | -190 M | -160 M | -131 M | -110 M | - | - | - | - |
Total Assets |
209 M | 181 M | 79 M | 113 M | 173 M | 203 M | 6.98 M | 23.5 M | 44 M | 43.5 M | 67.5 M | 84.8 M | - | - | - | - |
Cash and Cash Equivalents |
49.7 M | 163 M | 39.6 M | 24.1 M | 35.7 M | 169 M | 6.18 M | 19.4 M | 21.2 M | 36.4 M | 40 M | 68.8 M | 2.79 M | 2.41 M | - | - |
Book Value |
196 M | 167 M | 68.3 M | 102 M | 162 M | 199 M | 6.39 M | 20.4 M | 34.7 M | 38.4 M | 63.4 M | 82.5 M | - | - | - | - |
Total Shareholders Equity |
196 M | 167 M | 68.3 M | 102 M | 162 M | 199 M | -2.13 M | 20.4 M | 34.7 M | 38.4 M | 63.4 M | 82.5 M | -101 M | -86.7 M | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Balance Sheet Protara Therapeutics
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
2.12 M | 1.79 M | 3.36 M | 2.44 M | 2.75 M | 3.06 M | 3.36 M | 3.66 M | 3.95 M | 4.23 M | 4.48 M | 4.74 M | 4.98 M | 5.23 M | 5.47 M | 5.7 M | 5.93 M | 6.16 M | 6.38 M | 6.6 M | 6.82 M | 974 K | 999 K | 999 K | 999 K | 999 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
13.1 M | 10.7 M | 14.3 M | 12.3 M | 12.5 M | 10.1 M | 14.3 M | 12.3 M | 9.6 M | 9.73 M | 10.6 M | 11.5 M | 9.92 M | 11.6 M | 11.2 M | 9.41 M | 9.43 M | 9.02 M | 10.7 M | 10.3 M | 10.5 M | 4.29 M | 3.91 M | 3.91 M | 3.91 M | 3.91 M | 3.35 M | 3.35 M | 3.35 M | 3.35 M | 3.08 M | 3.08 M | 3.08 M | 3.08 M | 9.24 M | 9.24 M | 9.24 M | 9.24 M | 5.08 M | 5.08 M | 5.08 M | 5.08 M | 4.13 M | 4.13 M | 4.13 M | 4.13 M | 2.34 M | 2.34 M | 2.34 M | 2.34 M | 9.77 M | 9.77 M | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.95 M | 2.95 M | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-302 M | -320 M | -245 M | -285 M | -272 M | -257 M | -245 M | -232 M | -221 M | -211 M | -200 M | -190 M | -180 M | -169 M | -160 M | -121 M | -113 M | -105 M | -94 M | -83.8 M | -73 M | -60.2 M | -46.8 M | -46.8 M | -46.8 M | -46.8 M | -12.8 M | -12.8 M | -12.8 M | -12.8 M | -210 M | -210 M | -210 M | -210 M | -190 M | -190 M | -190 M | -190 M | -160 M | -160 M | -160 M | -160 M | -131 M | -131 M | -131 M | -131 M | -110 M | -110 M | -110 M | -110 M | -101 M | -101 M | - | - | - | - | - | - | - | - | - | - |
Total Assets |
209 M | 192 M | 181 M | 145 M | 157 M | 169 M | 181 M | 94.1 M | 102 M | 68.1 M | 79 M | 88.5 M | 95.1 M | 106 M | 113 M | 149 M | 155 M | 161 M | 173 M | 181 M | 189 M | 192 M | 203 M | 203 M | 203 M | 203 M | 1.22 M | 1.22 M | 1.22 M | 1.22 M | 23.5 M | 23.5 M | 23.5 M | 23.5 M | 44 M | 44 M | 44 M | 44 M | 43.5 M | 43.5 M | 43.5 M | 43.5 M | 67.5 M | 67.5 M | 67.5 M | 67.5 M | 84.8 M | 84.8 M | 84.8 M | 84.8 M | 5.66 M | 5.66 M | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
164 M | 14.7 M | 164 M | 12.6 M | 31.5 M | 91.5 M | 163 M | 52.5 M | 90.3 M | 53 M | 39.6 M | 34.5 M | 34.7 M | 21.8 M | 24.1 M | 48.2 M | 34.6 M | 26.2 M | 35.7 M | 40.7 M | 47.6 M | 58.2 M | 169 M | 169 M | 169 M | 169 M | 564 K | 564 K | 564 K | 564 K | 19.4 M | 19.4 M | 19.4 M | 19.4 M | 21.2 M | 21.2 M | 21.2 M | 21.2 M | 36.4 M | 36.4 M | 36.4 M | 36.4 M | 40 M | 40 M | 40 M | 40 M | 68.8 M | 68.8 M | 68.8 M | 68.8 M | 2.79 M | 2.79 M | - | - | 2.41 M | - | - | - | 3.27 M | - | - | - |
Book Value |
196 M | 181 M | 167 M | 132 M | 144 M | 158 M | 167 M | 81.8 M | 92 M | 58.4 M | 68.3 M | 77 M | 85.2 M | 94.8 M | 102 M | 139 M | 145 M | 152 M | 162 M | 170 M | 178 M | 188 M | 199 M | 199 M | 199 M | 199 M | -2.13 M | -2.13 M | -2.13 M | -2.13 M | 20.4 M | 20.4 M | 20.4 M | 20.4 M | 34.7 M | 34.7 M | 34.7 M | 34.7 M | 38.4 M | 38.4 M | 38.4 M | 38.4 M | 63.4 M | 63.4 M | 63.4 M | 63.4 M | 82.5 M | 82.5 M | 82.5 M | 82.5 M | -4.11 M | -4.11 M | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
167 M | 181 M | 68.3 M | 132 M | 144 M | 158 M | 167 M | 81.8 M | 92 M | 58.4 M | 68.3 M | 77 M | 85.2 M | 94.8 M | 102 M | 139 M | 145 M | 152 M | 162 M | 170 M | 178 M | 188 M | 199 M | 199 M | 199 M | 199 M | -2.13 M | -2.13 M | -2.13 M | -2.13 M | 4.78 M | 20.4 M | 20.4 M | 20.4 M | 34.7 M | 34.7 M | 34.7 M | 34.7 M | 38.4 M | 38.4 M | 38.4 M | 38.4 M | 63.4 M | 63.4 M | 63.4 M | 63.4 M | 82.5 M | 82.5 M | 82.5 M | 82.5 M | -101 M | -101 M | - | - | -86.7 M | - | - | - | -72.7 M | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Balance Sheet is a fundamental financial report of Protara Therapeutics, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
USA
Israel
Niderland
Canada
Danmark
Schweiz
Britain
